---
title: "Entyvio (vedolizumab) in ulcerative colitis: Clinical trials questions"
description: "Clinical trials questions on Entyvio (vedolizumab) in ulcerative colitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Comparative studies, and Outcome measures. Questions: How well does Entyvio IV work by Week 6 in ulcerative colitis (GEMINI I)? What were Entyvio IV Week 52 results in ulcerative colitis (GEMINI I)? Does Entyvio help ulcerative colitis patients get off steroids (GEMINI I)? Entyvio vs Humira: which had higher ulcerative colitis remission at Week 52 (VARSITY)? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab) in ulcerative colitis: Clinical trials questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)

Questions that apply to every indication of Entyvio are on [Entyvio (vedolizumab), all indications](https://www.evicenter.com/medical-information/entyvio).

## Study results

<a id="entyvio-gemini-week-6"></a>

### How well does Entyvio IV work by Week 6 in ulcerative colitis (GEMINI I)?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “Study Design<sup>1</sup>: Two randomized, double-blind, placebo-controlled studies enrolled adult patients with moderately to severely active UC who had failed at least 1 conventional therapy, including corticosteroids or immunomodulators and/or ≥1 anti-TNFα therapy. In UC Trial I, patients were randomized (3:2) to receive ENTYVIO 300 mg or placebo by intravenous infusion at Weeks 0 and 2. In UC Trial II, patients receiving ENTYVIO who demonstrated clinical response at Week 6 (from UC Trial I or an open-label cohort) were randomized (1:1:1) to receive either ENTYVIO 300 mg every 8 weeks, ENTYVIO 300 mg every 4 weeks, or placebo every 4 weeks. The ENTYVIO Q4W dosing regimen did not demonstrate additional clinical benefit over the Q8W dosing regimen. The Q4W dosing regimen is not the recommended dosing regimen.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=Study,not%20the%20recommended%20dosing%20regimen.)

> “In UC Trial I, 374 patients were randomized in a double-blind fashion (3:2) to receive 
> ENTYVIO 300 mg or placebo by intravenous infusion at Week 0 and Week 2. Efficacy 
> assessments were at Week 6. Concomitant stable dosages of aminosalicylates, 
> corticosteroids (prednisone dosage ≤30 mg/day or equivalent), and immunomodulators 
> (azathioprine or 6-mercaptopurine) were permitted through Week 6.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

> “Table 4. Proportion of Patients Meeting Efficacy Endpoints at Week 6 (UC Trial I)
> Endpoint
> Placebo
> N=149
> ENTYVIO
> IV
> N=225
> p-value
> Treatment
> Difference
> and
> 95% CI
> Clinical Response* at Week 6
> 26%
> 47%
> <0.001
> 22%
> (12%, 32%)
> Clinical Remission† at Week 6
> 5%
> 17%
> 0.001
> 12%
> (5%, 18%)
> Improvement of Endoscopic 
> Appearance of the Mucosa‡ 
> at Week 6
> 25%
> 41%
> 0.001
> 16%
> (6%, 26%)
> * Clinical response: reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an 
> accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore 
> of ≤1 point.
> †  Clinical remission: complete Mayo score of ≤2 points and no individual subscore >1 point.
> ‡  Improvement of endoscopic appearance of the mucosa: Mayo endoscopy subscore of 0 (normal or 
> inactive disease) or 1 (erythema, decreased vascular pattern, mild friability).”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

Note: The Entyvio HCP site calls UC Trials I and II of the Prescribing Information the GEMINI I trial. Table 4 columns are placebo (N=149), ENTYVIO IV 300 mg (N=225), p-value, and treatment difference with 95% CI, in that order.

<a id="entyvio-gemini-week-52"></a>

### What were Entyvio IV Week 52 results in ulcerative colitis (GEMINI I)?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “In UC Trial II, 373 patients were randomized in a double-blind fashion (1:1:1) to one of 
> the following regimens beginning at Week 6: intravenous ENTYVIO 300 mg every eight 
> weeks, intravenous ENTYVIO 300 mg every four weeks or placebo every four weeks. 
> Efficacy assessments were at Week 52. Concomitant aminosalicylates and corticosteroids 
> were permitted through Week 52. Concomitant immunomodulators (azathioprine or 
> 6-mercaptopurine) were permitted outside the U.S. but were not permitted beyond Week 6
> in the U.S.”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

> “Table 5. Proportion of Patients Meeting Efficacy Endpoints at Week 52* (UC Trial II)
> Endpoint
> Placebo† 
> N=126
> ENTYVIO
> IV
> Every 8 Weeks
> N=122
> p-value
> Treatment 
> Difference 
> and
> 95% CI
> Clinical Remission at
> Week 52
> 16%
> 42%
> <0.001
> 26%
> (15%, 37%)
> Clinical Response at both 
> Weeks 6 and 52
> 24%
> 57%
> <0.001
> 33%
> (21%, 45%)
> Improvement of 
> Endoscopic Appearance of 
> the Mucosa‡ at Week 52
> 20%
> 52%
> <0.001
> 32%
> (20%, 44%)
> Clinical Remission at both 
> Weeks 6 and 52
> 9%
> 21%
> 0.008
> 12%
> (3%, 21%)
> Corticosteroid-free Clinical 
> Remission<sup>§</sup>
> 14%<sup>§</sup>
> 31%<sup>§</sup>
> 0.012
> 18%
> (4%, 31%)
> * Patients must have achieved clinical response at Week 6 to continue into UC Trial II. This group includes 
> patients that were not in clinical remission at Week 6.
> † The placebo group includes those patients who received ENTYVIO at Week 0 and Week 2 and were 
> randomized to receive placebo from Week 6 through Week 52.
> ‡ Improvement of endoscopic appearance of the mucosa: Mayo endoscopy subscore of 0 (normal or 
> inactive disease) or 1 (erythema, decreased vascular pattern, mild friability) at Week 52.
> § Corticosteroid-free clinical remission: Assessed in the subgroup of patients who were receiving 
> corticosteroids at baseline and who were in clinical response at Week 6 (n=72 for placebo and n=70 
> for ENTYVIO every eight weeks). Corticosteroid-free clinical remission was defined as the proportion of 
> patients in this subgroup that discontinued corticosteroids by Week 52 and were in clinical remission 
> at Week 52.”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

Note: Only patients in clinical response at Week 6 after two ENTYVIO IV doses were randomized. Table 5 columns are placebo (N=126), ENTYVIO IV 300 mg every 8 weeks (N=122), p-value, and treatment difference with 95% CI, in that order; the every-4-week arm is not shown.

<a id="entyvio-steroid-free-remission"></a>

### Does Entyvio help ulcerative colitis patients get off steroids (GEMINI I)?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “In the subgroup of patients who achieved 
> clinical response at Week 6 and were receiving corticosteroid medication at baseline, a 
> greater proportion of patients in groups treated with intravenous ENTYVIO as compared to 
> placebo discontinued corticosteroids and were in clinical remission at Week 52 (Table 5).”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

> “Corticosteroid-free Clinical 
> Remission<sup>§</sup>
> 14%<sup>§</sup>
> 31%<sup>§</sup>
> 0.012
> 18%
> (4%, 31%)”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

> “§ Corticosteroid-free clinical remission: Assessed in the subgroup of patients who were receiving 
> corticosteroids at baseline and who were in clinical response at Week 6 (n=72 for placebo and n=70 
> for ENTYVIO every eight weeks). Corticosteroid-free clinical remission was defined as the proportion of 
> patients in this subgroup that discontinued corticosteroids by Week 52 and were in clinical remission 
> at Week 52.”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

Note: Values are placebo (14%), ENTYVIO IV 300 mg every 8 weeks (31%), p-value, and treatment difference with 95% CI, at Week 52 in UC Trial II, in that order.

<a id="entyvio-visible-1-pen"></a>

### How well does subcutaneous Entyvio work for ulcerative colitis (VISIBLE 1)?

Applies to: Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

> “Study Design<sup>1,16</sup>: A phase 3, randomized, double-blind, double-dummy, multicenter, placebo-controlled trial enrolled adult patients with moderately to severely active UC. At Week 6, patients who achieved clinical response were randomized to maintenance treatment with ENTYVIO SC + placebo IV, ENTYVIO IV + placebo SC, or placebo (IV and SC) in a 2:1:1 ratio, with stratification by concomitant CS use, clinical remission at Week 6, and previous anti-TNF failure or concomitant immunomodulator use. The ENTYVIO IV arm is a reference arm and not powered for statistical significance.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=results%20may%20vary.-,Study,not%20powered%20for%20statistical%20significance.)

> “All patients received open-label intravenous ENTYVIO 300 mg at Week 0 and Week 2. In 
> order to be randomized to treatment in SC UC Trial, patients had to be in clinical response at 
> Week 6. A total of 162 patients were randomized at Week 6 in a double-blind fashion (2:1) 
> to ENTYVIO 108 mg administered by subcutaneous injection or placebo every 2 weeks. 
> Efficacy assessments were at Week 52.”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

> “The primary endpoint was the proportion of patients in clinical remission defined as a Mayo score of
> ≤2 points and no individual subscore >1 point at Week 52. Secondary endpoints included 
> the proportion of patients with improvement of endoscopic appearance of the mucosa at 
> Week 52 and clinical response at both Weeks 6 and 52 (see Table 6).”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

> “Table 6. Proportion of Patients Meeting Efficacy Endpoints at Week 52* (SC UC Trial)
> Endpoint
> Placebo<sup>†</sup>
> ENTYVIO 108 mg
> SC
> Every 2 Weeks<sup>‡</sup>
> Estimate§ of Treatment 
> Difference vs. Placebo 
> (95% CI)
> Clinical Remission# at Week 52
> Total Population
> N=56
> 14%
> N=106
> 46%
> 32
> (20, 45)<sup>¶</sup>
> Prior TNF blocker
> failure
> N=20
> 10%
> N=40
> 35%
> Without prior TNF
> blocker failure
> N=36
> 17%
> N=66
> 53%
> Improvement of Endoscopic Appearance of the Mucosa at Week 52β
> Total Population
> N=56
> 21%
> N=106
> 57%
> 36
> (22, 49)<sup>¶</sup>
> Prior TNF blocker
> failure
> N=20
> 10%
> N=40
> 48%
> Without prior TNF
> blocker failure
> N=36
> 28%
> N=66
> 62%
> Clinical Response at both Weeks 6 and 52¥
> Total Population
> N=56
> 29%
> N=106
> 64%
> 36
> (21, 51)<sup>¶</sup>
> Prior TNF blocker
> failure
> N=20
> 20%
> N=40
> 68%
> Without prior TNF
> blocker failure
> N=36
> 33%
> N=66
> 62%
> * Patients must have achieved clinical response at Week 6 to continue into SC UC Trial.
> † The placebo group includes those subjects who received intravenous vedolizumab at Week 0 and Week 
> 2 and were randomized to receive placebo from Week 6 through Week 52.
> ‡ Starting at Week 6 following two intravenous doses of ENTYVIO 300 mg administered as an intravenous 
> infusion at Weeks 0 and 2.
> § Estimated treatment difference is based on the Cochran-Mantel-Haenszel method.
> # Clinical remission: Complete Mayo score of ≤2 points and no individual subscore >1 point at Week 52.
> ¶ p <0.001
> β Improvement of endoscopic appearance of the mucosa: Mayo endoscopic subscore of ≤1 point.
> ¥ Clinical response: reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an 
> accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore 
> of ≤1 point.”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

> “Maintenance of remission at Week 52 in the subgroup of patients who were in remission 
> at Week 6, was 64% (16/25) in the ENTYVIO-treated group compared to 20% (3/15) in the 
> placebo group. The treatment difference was 44% (95% CI: 9%, 69%).”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

> “No statistically significant differences in durable clinical remission or CS-free clinical remission at Week 52 vs placebo<sup>16‡§</sup>”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=No%20statistically%20significant%20differences%20in,remission%20at%20Week%2052%20vs)

> “<sup>‡</sup>Durable clinical remission was defined as a total Mayo score of ≤2 and no individual subscore >1 at both Weeks 6 and 52.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=clinical%20remission%20was%20defined%20as%20a%20total,both%20Weeks%206%20and%2052.)

> “<sup>§</sup>CS-free remission was defined as patients using oral corticosteroids at Week 0 who have discontinued oral corticosteroids and are in clinical remission at Week 52.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=remission%20was%20defined%20as%20patients,clinical%20remission%20at%20Week%2052.)

Note: The Prescribing Information calls VISIBLE 1 the SC UC Trial (NCT02611830). Within each row of Table 6, the placebo N and percentage come first, then the ENTYVIO 108 mg subcutaneous every 2 weeks N and percentage, then the estimated treatment difference with 95% CI for the total population. The 64% versus 20% figure is for the subgroup in remission at Week 6; the efficacy page reports durable clinical remission for the overall population.

## Comparative studies

<a id="entyvio-varsity-vs-humira"></a>

### Entyvio vs Humira: which had higher ulcerative colitis remission at Week 52 (VARSITY)?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “Study Design<sup>2</sup>: VARSITY was a double-blind, double-dummy, active-controlled trial that compared ENTYVIO with Humira<sup>®</sup> in adults with moderately to severely active ulcerative colitis. Eligible patients were randomized (1:1) to receive ENTYVIO and placebo, or Humira<sup>®</sup> and placebo. After induction, patients remained in their respective treatment group throughout the maintenance phase (treat-through design). Previous exposure to TNFα inhibitors other than Humira<sup>®</sup> was permitted in up to 25% of patients. Patients who had no response or lost response to conventional therapies were eligible. Dosing was consistent with the US product label for both ENTYVIO and Humira<sup>®</sup>; no dose escalation was permitted for either treatment group.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=subscore%20%3E1%20point.-,Study,permitted%20for%20either%20treatment%20group.)

> “In clinical remission at Week 52 in the overall population<sup>2,3</sup>*<sup>†</sup>”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=%28adalimumab%29-,In%20clinical%20remission%20at%20Week%2052%20in%20the%20overall)

> “VARSITY primary end point (overall population): ENTYVIO IV 31% (n=383) vs 23% (n=386) with Humira<sup>®</sup> (P=0.006; 95% CI: 3%, 15%)<sup>2</sup>”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=VARSITY%20primary%20end%20point%20%28overall,%28P%3D0.006%3B%2095%25%20CI%3A%203%25%2C)

> “<sup>†</sup>Clinical remission was defined as a complete Mayo Score of ≤2 points and no subscore >1 point.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=remission%20was%20defined%20as%20a%20complete%20Mayo%20Score%20of%20%E2%89%A42%20points%20and%20no%20subscore%20%3E1%20point.,-Study)

> “ENTYVIO demonstrated superiority to Humira® in endoscopic improvement at Week 52<sup>2</sup>*”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=ENTYVIO%20demonstrated%20superiority%20to%20Humira%C2%AE%20in%20endoscopic%20improvement%20at%20Week)

> “*Endoscopic improvement was defined as a Mayo endoscopic subscore of ≤1 point.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=%2AEndoscopic%20improvement%20was%20defined%20as%20a%20Mayo%20endoscopic%20subscore%20of%20%E2%89%A41%20point.)

> “Nonsignificant differences in corticosteroid-free remission at Week 52<sup>9,10</sup>*”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=Nonsignificant%20differences%20in%20corticosteroid%2Dfree%20remission%20at%20Week)

> “Approximately 36% of randomized patients were on corticosteroids at baseline.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=Approximately%2036%25%20of%20randomized%20patients%20were%20on%20corticosteroids%20at%20baseline.)

Note: The page labels the VARSITY comparison ENTYVIO IV vs Humira (adalimumab). The page states the endoscopic improvement and corticosteroid-free remission results without percentages and does not state which arm had the higher corticosteroid-free remission rate.

## Outcome measures

<a id="entyvio-mayo-score"></a>

### How is ulcerative colitis remission defined in Entyvio trials (Mayo score)?

> “The Mayo score ranges from 0 to 12 and has four subscales that 
> are each scored from zero (normal) to three (most severe): stool frequency, rectal bleeding, 
> findings on endoscopy, and physician global assessment.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

> “†  Clinical remission: complete Mayo score of ≤2 points and no individual subscore >1 point.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

> “* Clinical response: reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an 
> accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore 
> of ≤1 point.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

## Related pages
- [Medical information: Entyvio (vedolizumab): Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)
- [Indication](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/guidelines)
